cd11b fitc Search Results


95
Miltenyi Biotec anti cd11b fitc
Anti Cd11b Fitc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cd11b fitc/product/Miltenyi Biotec
Average 95 stars, based on 1 article reviews
anti cd11b fitc - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

91
Bioss anti‑cd11b
Anti‑Cd11b, supplied by Bioss, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti‑cd11b/product/Bioss
Average 91 stars, based on 1 article reviews
anti‑cd11b - by Bioz Stars, 2026-03
91/100 stars
  Buy from Supplier

95
Miltenyi Biotec rat anti mouse cd11b fitc
Rat Anti Mouse Cd11b Fitc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rat anti mouse cd11b fitc/product/Miltenyi Biotec
Average 95 stars, based on 1 article reviews
rat anti mouse cd11b fitc - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

96
Miltenyi Biotec anti cd11b
Anti Cd11b, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cd11b/product/Miltenyi Biotec
Average 96 stars, based on 1 article reviews
anti cd11b - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

99
Miltenyi Biotec cd11b c fitc
Cd11b C Fitc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd11b c fitc/product/Miltenyi Biotec
Average 99 stars, based on 1 article reviews
cd11b c fitc - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

93
Proteintech cd11b fitc
Cd11b Fitc, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd11b fitc/product/Proteintech
Average 93 stars, based on 1 article reviews
cd11b fitc - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

94
Cytek Biosciences anti mouse cd11b fitc tonbo 35 0112 u500
Anti Mouse Cd11b Fitc Tonbo 35 0112 U500, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti mouse cd11b fitc tonbo 35 0112 u500/product/Cytek Biosciences
Average 94 stars, based on 1 article reviews
anti mouse cd11b fitc tonbo 35 0112 u500 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

93
Cytek Biosciences pe conjugated monoclonal anti cd11b
Pe Conjugated Monoclonal Anti Cd11b, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pe conjugated monoclonal anti cd11b/product/Cytek Biosciences
Average 93 stars, based on 1 article reviews
pe conjugated monoclonal anti cd11b - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

95
R&D Systems fitc anti cd11b
Fitc Anti Cd11b, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fitc anti cd11b/product/R&D Systems
Average 95 stars, based on 1 article reviews
fitc anti cd11b - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

94
Miltenyi Biotec human cd11b fitc
Human Cd11b Fitc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human cd11b fitc/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
human cd11b fitc - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

91
Hycult Biotech human cd11b fitc
A Map of the payload for U6-shRNA vectors. This is a bicistronic construct con-taining U6-shRNA followed by PGK-Puro-T2A-BFP. B Secondary structure of U6-driven shRNA hairpin. The predicted transcript contains a 21nt dsRNA stretch separated by a 9nt hairpin derived from hsa-miR21. C <t>CD11b</t> expression assessed at day 20 of differentiation by flow cytometry. Cells underwent staggered transduction during differentiation with lentivirus carrying three different U6-driven shRNA’s targeting ITGAM, as well as a nontargetign control. D Map of the payload for the tagBFP-miRshRNA vector, with the shRNA in the 3’UTR of tagBFP. In all maps, lentiviral elements up-and downstream of the payload are not shown. E Secondary structures of endogenous hsa-miR-30a (left) and miR30a-ITGAM-sh5 which contains a guide sequence targeted to the 3’LTR of ITGAM . The structure of the synthetic shRNA differs from endogenous in missing two bulges: a 1nt mismatch at position 12, and a 2nt mismatch at positions 30-32. All structures were generated with the RNAfold Webtool . F Experiments showing CD11b expression by flow cytometry at day 20 of differ-entiation after staggered transduction with lentivirus carrying miR-shRNA’s. Five different miR-shRNA’s targeted to ITGAM as well as a nontargeting control were tested. Data for both tagBFP + cells (top) or all live single cells (bottom) are shown. UT, untreated; NT, nontargeting shRNA; ITGsh1-5, shRNA’s 1-5 targeted to ITGAM . For and , individual data from six distinct donors are shown as dots, with horizontal bars indicating the median of each group with the interquartile range depicted by error bars. Asterisks indi-cate statistical significance (Friedman’s test) as detailed by bars between relevant groups: *p ≤ 0.05;**p ≤ 0.01; ***p ≤ 0.001. Gating strategy for all flow cytometry is shown in Fig. S1C, and was obtained on the Attune NxT flow cytometer.
Human Cd11b Fitc, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human cd11b fitc/product/Hycult Biotech
Average 91 stars, based on 1 article reviews
human cd11b fitc - by Bioz Stars, 2026-03
91/100 stars
  Buy from Supplier

93
Proteintech fluorescein isothiocyanate fitc fluorescent tagged antibodies
A Map of the payload for U6-shRNA vectors. This is a bicistronic construct con-taining U6-shRNA followed by PGK-Puro-T2A-BFP. B Secondary structure of U6-driven shRNA hairpin. The predicted transcript contains a 21nt dsRNA stretch separated by a 9nt hairpin derived from hsa-miR21. C <t>CD11b</t> expression assessed at day 20 of differentiation by flow cytometry. Cells underwent staggered transduction during differentiation with lentivirus carrying three different U6-driven shRNA’s targeting ITGAM, as well as a nontargetign control. D Map of the payload for the tagBFP-miRshRNA vector, with the shRNA in the 3’UTR of tagBFP. In all maps, lentiviral elements up-and downstream of the payload are not shown. E Secondary structures of endogenous hsa-miR-30a (left) and miR30a-ITGAM-sh5 which contains a guide sequence targeted to the 3’LTR of ITGAM . The structure of the synthetic shRNA differs from endogenous in missing two bulges: a 1nt mismatch at position 12, and a 2nt mismatch at positions 30-32. All structures were generated with the RNAfold Webtool . F Experiments showing CD11b expression by flow cytometry at day 20 of differ-entiation after staggered transduction with lentivirus carrying miR-shRNA’s. Five different miR-shRNA’s targeted to ITGAM as well as a nontargeting control were tested. Data for both tagBFP + cells (top) or all live single cells (bottom) are shown. UT, untreated; NT, nontargeting shRNA; ITGsh1-5, shRNA’s 1-5 targeted to ITGAM . For and , individual data from six distinct donors are shown as dots, with horizontal bars indicating the median of each group with the interquartile range depicted by error bars. Asterisks indi-cate statistical significance (Friedman’s test) as detailed by bars between relevant groups: *p ≤ 0.05;**p ≤ 0.01; ***p ≤ 0.001. Gating strategy for all flow cytometry is shown in Fig. S1C, and was obtained on the Attune NxT flow cytometer.
Fluorescein Isothiocyanate Fitc Fluorescent Tagged Antibodies, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fluorescein isothiocyanate fitc fluorescent tagged antibodies/product/Proteintech
Average 93 stars, based on 1 article reviews
fluorescein isothiocyanate fitc fluorescent tagged antibodies - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

Image Search Results


A Map of the payload for U6-shRNA vectors. This is a bicistronic construct con-taining U6-shRNA followed by PGK-Puro-T2A-BFP. B Secondary structure of U6-driven shRNA hairpin. The predicted transcript contains a 21nt dsRNA stretch separated by a 9nt hairpin derived from hsa-miR21. C CD11b expression assessed at day 20 of differentiation by flow cytometry. Cells underwent staggered transduction during differentiation with lentivirus carrying three different U6-driven shRNA’s targeting ITGAM, as well as a nontargetign control. D Map of the payload for the tagBFP-miRshRNA vector, with the shRNA in the 3’UTR of tagBFP. In all maps, lentiviral elements up-and downstream of the payload are not shown. E Secondary structures of endogenous hsa-miR-30a (left) and miR30a-ITGAM-sh5 which contains a guide sequence targeted to the 3’LTR of ITGAM . The structure of the synthetic shRNA differs from endogenous in missing two bulges: a 1nt mismatch at position 12, and a 2nt mismatch at positions 30-32. All structures were generated with the RNAfold Webtool . F Experiments showing CD11b expression by flow cytometry at day 20 of differ-entiation after staggered transduction with lentivirus carrying miR-shRNA’s. Five different miR-shRNA’s targeted to ITGAM as well as a nontargeting control were tested. Data for both tagBFP + cells (top) or all live single cells (bottom) are shown. UT, untreated; NT, nontargeting shRNA; ITGsh1-5, shRNA’s 1-5 targeted to ITGAM . For and , individual data from six distinct donors are shown as dots, with horizontal bars indicating the median of each group with the interquartile range depicted by error bars. Asterisks indi-cate statistical significance (Friedman’s test) as detailed by bars between relevant groups: *p ≤ 0.05;**p ≤ 0.01; ***p ≤ 0.001. Gating strategy for all flow cytometry is shown in Fig. S1C, and was obtained on the Attune NxT flow cytometer.

Journal: bioRxiv

Article Title: Efficient Methods for Target Gene Manipulation in Haematopoietic Stem Cell Derived Human Neutrophils

doi: 10.1101/2023.06.17.545406

Figure Lengend Snippet: A Map of the payload for U6-shRNA vectors. This is a bicistronic construct con-taining U6-shRNA followed by PGK-Puro-T2A-BFP. B Secondary structure of U6-driven shRNA hairpin. The predicted transcript contains a 21nt dsRNA stretch separated by a 9nt hairpin derived from hsa-miR21. C CD11b expression assessed at day 20 of differentiation by flow cytometry. Cells underwent staggered transduction during differentiation with lentivirus carrying three different U6-driven shRNA’s targeting ITGAM, as well as a nontargetign control. D Map of the payload for the tagBFP-miRshRNA vector, with the shRNA in the 3’UTR of tagBFP. In all maps, lentiviral elements up-and downstream of the payload are not shown. E Secondary structures of endogenous hsa-miR-30a (left) and miR30a-ITGAM-sh5 which contains a guide sequence targeted to the 3’LTR of ITGAM . The structure of the synthetic shRNA differs from endogenous in missing two bulges: a 1nt mismatch at position 12, and a 2nt mismatch at positions 30-32. All structures were generated with the RNAfold Webtool . F Experiments showing CD11b expression by flow cytometry at day 20 of differ-entiation after staggered transduction with lentivirus carrying miR-shRNA’s. Five different miR-shRNA’s targeted to ITGAM as well as a nontargeting control were tested. Data for both tagBFP + cells (top) or all live single cells (bottom) are shown. UT, untreated; NT, nontargeting shRNA; ITGsh1-5, shRNA’s 1-5 targeted to ITGAM . For and , individual data from six distinct donors are shown as dots, with horizontal bars indicating the median of each group with the interquartile range depicted by error bars. Asterisks indi-cate statistical significance (Friedman’s test) as detailed by bars between relevant groups: *p ≤ 0.05;**p ≤ 0.01; ***p ≤ 0.001. Gating strategy for all flow cytometry is shown in Fig. S1C, and was obtained on the Attune NxT flow cytometer.

Article Snippet: The following antibodies or staining reagents were used: Mouse-anti human CD11b-FITC (Bear-1, Hycult Biotech), mouse-anti human CD62L-Alexa Fluor 647 (DREG-56, Biolegend), mouse-anti human CD16-Pacific blue (3G8, Biolegend), mouse anti-human CD11b-Alexa Fluor 647 (ICRF44, Biolegend), Annexin V-FITC (Thermofisher Scientific), propidium iodide (Biolegend).

Techniques: shRNA, Construct, Derivative Assay, Expressing, Flow Cytometry, Transduction, Control, Plasmid Preparation, Sequencing, Generated

A Differentiation timeline with nucleofection (red) after 3 days of StemSpan preconditioning. Nucleofected cells were rested in media containing StemSpan and 5 µ M Z-VAD-FMK, a pan-caspase inhibitor, to mitigate cell losses after nucleofection. Cells were then differentiated G-CSF at 10ng/mL for 14 days. B,C CD11b expression by flow cytom-etry at day 20. MFI (B), and total CD11b - the product of percent positive and MFI of the positive cells (C) are shown. D Genomic indel profiles obtained by Sanger sequencing and Tracking of Indels by DEcomposition (TIDE) analysis comparing ITGAM guide RNA 1 compared to donor-specific nontargeting controls. The Cas9 cut site is shown as 0nt, and insertions (right, positive) and deletions (left, negative) are expressed as a percentage of total sequences. Data at 0nt are indicate no sequence change. Total efficacy is shown at the left of the graph and is the sum of percentage indels. E,F Functional capacities of CRISPR-edited neutrophils. Phagocytosis of serum opsonised pHrodo red conjugated bioparticles of S. aureus (SA) and E. coli (EC) are shown in (E), and oxidative response by DHR fluores-cence are shown in (F). NT, Nontargeting guide; ITGAM KO, ITGAM gRNA1. For and 5E-F, individual data from six distinct donors are shown as dots, with horizontal bars indicating the median of each group with the interquartile range depicted by error bars. Asterisks indicate statistical significance (Friedman’s test) as detailed by bars between rel-evant groups: *p ≤ 0.05;**p ≤ 0.01; ***p ≤ 0.001. Gating strategies are shown in Fig. S1D and all flow data was obtained on the Attune NxT flow cytometer. Example outputs of TIDE analysis are shown in Fig.S2.

Journal: bioRxiv

Article Title: Efficient Methods for Target Gene Manipulation in Haematopoietic Stem Cell Derived Human Neutrophils

doi: 10.1101/2023.06.17.545406

Figure Lengend Snippet: A Differentiation timeline with nucleofection (red) after 3 days of StemSpan preconditioning. Nucleofected cells were rested in media containing StemSpan and 5 µ M Z-VAD-FMK, a pan-caspase inhibitor, to mitigate cell losses after nucleofection. Cells were then differentiated G-CSF at 10ng/mL for 14 days. B,C CD11b expression by flow cytom-etry at day 20. MFI (B), and total CD11b - the product of percent positive and MFI of the positive cells (C) are shown. D Genomic indel profiles obtained by Sanger sequencing and Tracking of Indels by DEcomposition (TIDE) analysis comparing ITGAM guide RNA 1 compared to donor-specific nontargeting controls. The Cas9 cut site is shown as 0nt, and insertions (right, positive) and deletions (left, negative) are expressed as a percentage of total sequences. Data at 0nt are indicate no sequence change. Total efficacy is shown at the left of the graph and is the sum of percentage indels. E,F Functional capacities of CRISPR-edited neutrophils. Phagocytosis of serum opsonised pHrodo red conjugated bioparticles of S. aureus (SA) and E. coli (EC) are shown in (E), and oxidative response by DHR fluores-cence are shown in (F). NT, Nontargeting guide; ITGAM KO, ITGAM gRNA1. For and 5E-F, individual data from six distinct donors are shown as dots, with horizontal bars indicating the median of each group with the interquartile range depicted by error bars. Asterisks indicate statistical significance (Friedman’s test) as detailed by bars between rel-evant groups: *p ≤ 0.05;**p ≤ 0.01; ***p ≤ 0.001. Gating strategies are shown in Fig. S1D and all flow data was obtained on the Attune NxT flow cytometer. Example outputs of TIDE analysis are shown in Fig.S2.

Article Snippet: The following antibodies or staining reagents were used: Mouse-anti human CD11b-FITC (Bear-1, Hycult Biotech), mouse-anti human CD62L-Alexa Fluor 647 (DREG-56, Biolegend), mouse-anti human CD16-Pacific blue (3G8, Biolegend), mouse anti-human CD11b-Alexa Fluor 647 (ICRF44, Biolegend), Annexin V-FITC (Thermofisher Scientific), propidium iodide (Biolegend).

Techniques: Expressing, Sequencing, Functional Assay, CRISPR, Flow Cytometry